Immunotherapy - risk/benefit in food allergy

Area of Science:

• Immunology
• Allergology
• Clinical Medicine

Background:

• Food allergy is a significant health issue, particularly in Western countries, affecting approximately 6% of children.
• Current management relies solely on strict dietary avoidance due to the lack of approved therapeutic treatments.
• The growing prevalence necessitates the development of effective treatment options beyond avoidance.

Purpose of the Study:

• To explore allergen-specific immunotherapy (SIT) as a potential active treatment for food allergies.
• To evaluate various routes of SIT administration, including oral, sublingual, and epicutaneous methods.
• To investigate novel strategies, such as tolerogenic peptides, for improving SIT safety and efficacy.

Main Methods:

• Review of current research on different routes of allergen-specific immunotherapy (SIT) for food allergies.
• Analysis of the efficacy and safety profiles of established and emerging SIT approaches.
• Exploration of tolerogenic peptides as a strategy to enhance SIT safety by preventing IgE cross-linking.

Main Results:

• Various SIT routes can induce temporary tolerance, with oral immunotherapy (OIT) being extensively studied.
• Sublingual and epicutaneous SIT are being investigated for improved safety and convenience, but their capacity for long-term tolerance is uncertain.
• High rates of adverse reactions and the inability to achieve permanent tolerance highlight the need for refined SIT strategies.

Conclusions:

• Allergen-specific immunotherapy (SIT) holds promise for treating food allergies, but is not yet clinically ready.
• Tolerogenic peptides represent a promising strategy to improve SIT safety and potentially achieve permanent tolerance.
• Further research and clinical studies are essential to establish SIT as a standard treatment for food allergy.